AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03761199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body cryostimulation
Description: In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.
Study NCT03761199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: whole body cryostimulation
Description: In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.
Study NCT03386409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free safe firearm storage device distribution
Description: Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
Study NCT00559572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational group sessions
Description: Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
Study NCT03386409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low cost safe firearm storage device
Description: Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
Study NCT03446417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-e4
Description: Oral dose, tablet, daily dosing
Study NCT01821456 — intervention group
Intervention type: DRUG
Intervention: Antiinfectives
Description: To analyze to efficacy of (novel) drug therapies
Study NCT01407796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin (E. coli O:113, Reference Endotoxin)
Study NCT01407796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F](+/-)NOS
Study NCT02584361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Round window approach
Description: In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
Study NCT02584361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cochleostomy
Description: In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
Study NCT02097342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
Study NCT02097342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet placebo per oral, once daily will be given to 10 patients for 6 months
Study NCT02097342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose
Description: Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
Study NCT04066634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivio System
Description: The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
Study NCT04112979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: 45 dB SL, normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
Study NCT04112979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother's lap
Description: 45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
Study NCT04112979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soundproof earplugs
Description: Disposable foam earplugs with a noise attenuation of at least 30 dB
Study NCT01330654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: 50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
Study NCT04454645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mABC
Description: Intervention targets parenting sensitivity and nurturance.
Study NCT04454645 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mDEF
Description: Intervention targets parenting enhancing infant cognitive development
Study NCT03464916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR2 Anti-CD38 A2 CAR-T Cells
Description: Autologous IV infusion; dose-escalation
Study NCT02758301 — intervention group
Intervention type: DEVICE
Intervention: Reveal LINQ™ Insertable Cardiac Monitor (ICM)
Description: Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
Study NCT01793259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate prefilled pen
Study NCT01793259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate prefilled syringe
Study NCT02062983 — intervention group
Intervention type: DRUG
Intervention: Herceptin
Description: Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.~Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression.
Study NCT01522430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal angiography followed by renal sympathetic denervation
Description: Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
Study NCT01522430 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal angiography alone
Description: Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
Study NCT02713867 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Study NCT02713867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01028170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide and hypertonic saline solution
Description: 250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
Study NCT01028170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide
Description: 80-160 mg furosemide (Given over 5 min IV twice a day)
Study NCT04110470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
Study NCT04110470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: No-Xray
Description: These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
Study NCT04180787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage Consumption
Description: Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
Study NCT04180787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beverage Consumption
Description: Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
Study NCT00628147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band imaging colonoscope
Description: Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
Study NCT01814670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: 20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
Study NCT03613935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 2
Description: Comparison with products 1, 3, and 4
Study NCT02412709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QTScreen ECG Recorder
Description: Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
Study NCT02412709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QTScreen ECG Recorder
Description: Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
Study NCT02636712 — intervention group
Intervention type: DEVICE
Intervention: ImageReady™ MR Conditional Pacing System
Study NCT00877721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Mobility Improvement in the eLderly by using the SMILING system
Description: The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
Study NCT05190055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bone graft delivery system/wiltrom interbody fusion system/wiltrom spinal fixation system
Description: After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. In the case of the device group, a novel filler tube with an integrated threaded rod, which can be connected to a surgical drill, A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
Study NCT05190055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wiltrom interbody fusion system/wiltrom spinal fixation system
Description: After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted, exposing the lumber vertebras encompassing the facet joints. The facet joints were removed, and decompression was performed. The diseased disc nucleus was then excised before filling in the bone substitutes. For the control group, the bone substitutes were filled in the disc space manually using a bone grafting funnel. A PEEK interbody fusion cage was then placed into the disc space followed by fixation with pedicle screws.
Study NCT04418908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix acetate, 0.25 mg/day
Description: All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).
Study NCT01600053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
Study NCT03813381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie and protein restriction diet
Description: Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention.
Study NCT02710942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPHERE
Study NCT04418908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetrorelix acetate, 0.25 mg/day
Description: All participants self-administered GnRHant daily between the baseline and follow-up visits (cetrorelix acetate, 0.25 mg/day).
Study NCT04418908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release
Description: Active estradiol transdermal patch.
Study NCT04418908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Placebo patch designed to match active Climara patches.
Study NCT03845842 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Volitional help sheet
Description: Participants are asked to choose from a list of strategies for avoiding cannabis use.
Study NCT02710942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISM
Study NCT03118830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
Study NCT03118830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrorelix
Description: Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
Study NCT03118830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Follicle Stimulating Hormone
Description: Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
Study NCT02421601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Condoliase
Description: 1.25 U, intradiscal injection, one time
Study NCT01662947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117
Description: Systolic, Diastolic pressure.
Study NCT01662947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2
Description: Systolic, Diastolic pressure
Study NCT01873690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Once, 400 mg IV
Study NCT00559572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time and attention control group sessions
Description: Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
Study NCT01873690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% Dextrose in water
Study NCT00996346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan&Temsirolimus:Arm1, Level 1
Description: Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
Study NCT00996346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan&Temsirolimus:Arm 1, Level 2
Description: Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
Study NCT00996346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan&Temsirolimus:Arm 2, Level 1
Description: Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
Study NCT03845842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Description: Participants are asked to choose from a list of strategies for avoiding cannabis use.
Study NCT03619135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
Study NCT03619135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No use of the Buzzy (standard IV access techniques)
Study NCT02108665 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiographic hysterosalpingography
Study NCT02108665 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic resonance imaging hysterosalpingography
Study NCT01884415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV vaccine
Description: Patients receive a second cycle of vaccination
Study NCT01884415 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBV vaccine
Description: Patients receive vaccination according to the guidelines.
Study NCT03613935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 2
Description: Comparison with products 1, 3, and 4
Study NCT01475162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
Study NCT03631420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Derived-Mesenchymal Stem Cells
Description: Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
Study NCT03613935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 3
Description: Comparison with products 1, 2, and 4
Study NCT03613935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 3
Description: Comparison with products 1, 2, and 4
Study NCT03613935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Product 4
Description: Comparison with products 1, 2, and 3
Study NCT03613935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Product 4
Description: Comparison with products 1, 2, and 3
Study NCT00654173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT00654173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study NCT00654173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT00664742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL®
Description: Fluvastatin extended release 80 mg
Study NCT01817894 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eflornithine cream 11.5 w/w %
Description: Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
Study NCT00729547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: enhance relative activity level of left frontal activity